Gulf Trader
عضو نشط
- التسجيل
- 2 نوفمبر 2006
- المشاركات
- 718
اغلاق الامس 2.28
اعلي سعر لليوم 4.75
الاعلي سنوي 3.80
8:23AM EpiCept says findings presented show potential of Azixa to act as a vascular disrupting agent (EPCT) 2.28 : Co announced that that studies characterizing a dual mode of action for Azixa, a compound licensed by the co to Myriad Genetics (MYGN), for the treatment of primary and secondary brain tumors, were presented at the annual meeting of the American Association of Cancer Research in Los Angeles, California. The findings presented by MYGN indicate the potential of Azixa to act as a vascular disrupting agent, in addition to its previously demonstrated apoptosis inducing capabilities.
اعلي سعر لليوم 4.75
الاعلي سنوي 3.80
8:23AM EpiCept says findings presented show potential of Azixa to act as a vascular disrupting agent (EPCT) 2.28 : Co announced that that studies characterizing a dual mode of action for Azixa, a compound licensed by the co to Myriad Genetics (MYGN), for the treatment of primary and secondary brain tumors, were presented at the annual meeting of the American Association of Cancer Research in Los Angeles, California. The findings presented by MYGN indicate the potential of Azixa to act as a vascular disrupting agent, in addition to its previously demonstrated apoptosis inducing capabilities.